INT7825

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.47
First Reported 1992
Last Reported 2009
Negated 0
Speculated 0
Reported most in Abstract
Documents 7
Total Number 7
Disease Relevance 0.89
Pain Relevance 5.92

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Cck) extracellular region (Cck) DNA binding (Cck)
Anatomy Link Frequency
liver 2
brain 2
central nervous system 2
Cck (Mus musculus)
Pain Link Frequency Relevance Heat
Cholecystokinin 124 100.00 Very High Very High Very High
Opioid 16 100.00 Very High Very High Very High
Delta opioid receptors 4 99.98 Very High Very High Very High
Central nervous system 3 99.68 Very High Very High Very High
analgesia 6 99.16 Very High Very High Very High
Neuropeptide 10 99.12 Very High Very High Very High
opioid receptor 26 98.80 Very High Very High Very High
Potency 2 98.80 Very High Very High Very High
Antinociceptive 4 96.96 Very High Very High Very High
Enkephalin 19 95.36 Very High Very High Very High
Disease Link Frequency Relevance Heat
INFLAMMATION 10 94.04 High High
Injury 2 86.40 High High
Ulcers 1 79.96 Quite High
Pain 14 78.32 Quite High
Disease 8 78.04 Quite High
Recurrence 1 77.80 Quite High
Inflammatory Bowel Disease 30 71.72 Quite High
Arthralgia 18 45.28 Quite Low
Disorder Of Lipid Metabolism 1 15.96 Low Low
Peripheral Arterial Disease 1 7.92 Low Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In this work we have shown, by in vivo binding experiments, that the endogenous enkephalins, protected from degrading enzymes by mixed inhibitors such as kelatorphan and N-[(R,S)-2-benzyl-3-[(S)-2-amino-4-methylthiobutyldithio]-1-oxo pro pyl]- L-phenylalanine benzyl ester (RB 101), a systemically active prodrug, modulate CCK release in mouse brain, leading to an overall increase in the extracellular levels of CCK.
Positive_regulation (leading) of Localization (release) of CCK in brain associated with enkephalin and cholecystokinin
1) Confidence 0.47 Published 1992 Journal J. Neurochem. Section Abstract Doc Link 1357099 Disease Relevance 0 Pain Relevance 0.70
The number of Fos immunoreactive cells distinctly increased after i.p. application of CCK-8 (0.4 ?
Positive_regulation (increased) of Localization (application) of CCK-8 associated with cholecystokinin
2) Confidence 0.42 Published 2008 Journal BMC Neurosci Section Body Doc Link PMC2587474 Disease Relevance 0 Pain Relevance 0.58
These results suggest that stimulation of delta 2-opioid receptors potentiates micro-opioid analgesia in the hot-plate test in mice through an increase in endogenous cholecystokinin release, while activation of delta 1-opioid receptors could decrease it.
Positive_regulation (increase) of Localization (release) of cholecystokinin associated with opioid receptor, cholecystokinin, opioid and analgesia
3) Confidence 0.41 Published 1996 Journal Neuroscience Section Abstract Doc Link 8951884 Disease Relevance 0 Pain Relevance 2.05
Duodenal administration of seal oil to the principal site of lipid digestion yields free long chain n-3 PUFAs known to stimulate cholecystokinin (CCK) release [35].
Positive_regulation (stimulate) of Localization (release) of CCK associated with cholecystokinin
4) Confidence 0.28 Published 2006 Journal Lipids Health Dis Section Body Doc Link PMC1471788 Disease Relevance 0.72 Pain Relevance 0.54
Furthermore, we have previously shown that activation of delta-opioid receptors increases cholecystokinin release in the central nervous system, resulting in a potentiation of micro-opioid antinociceptive responses, and the respective role of delta 1- and delta 2-opioid receptors in this facilitatory effect has now been evaluated.
Positive_regulation (increases) of Localization (release) of cholecystokinin in central nervous system associated with opioid receptor, central nervous system, delta opioid receptors, antinociceptive, opioid and cholecystokinin
5) Confidence 0.27 Published 1996 Journal Neuroscience Section Abstract Doc Link 8951884 Disease Relevance 0 Pain Relevance 1.22
The observation that 95% glucose with 5% soybean oil did not cause a phase advance of the liver clock could be attributed to potency differences of fat and oil or the level of protein and fat required for CCK release [23]–[25].
Positive_regulation (required) of Localization (release) of CCK in liver associated with cholecystokinin and potency
6) Confidence 0.26 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2734168 Disease Relevance 0 Pain Relevance 0.21
Centrally and /or peripherally injected neuropeptides, such as amylin, adrenomedullin, bombesin, cholecystokinin, neurotensin, opioid peptides, thyreotropin releasing hormone and vasoactive intestinal peptide, influence both the acid secretion and the gastric mucosal lesions induced by different ulcerogens.
Positive_regulation (induced) of Localization (secretion) of cholecystokinin associated with neuropeptide, opioid and cholecystokinin
7) Confidence 0.04 Published 2004 Journal Curr Top Med Chem Section Abstract Doc Link 14754377 Disease Relevance 0.17 Pain Relevance 0.62

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox